Erytech-SQZ collaboration to ‘realize immune-modulating potential’ 11-Jul-2019 By Maggie Lynch Erytech entered an agreement with SQZ to advance RBC-based therapeutics for immune modulation using the latter’s platform.
CTI opens new offices to support anticipated demand for regenerative medicine expertise 11-Jun-2019 By Melissa Fassbender The CRO is adding two new offices in the US to support what has been significant growth over the past several years from pharma and biotech customers working in rare diseases and immune-oncology.